Invesco
RNAC icon

Invesco’s Cartesian Therapeutics RNAC Stock Holding History

Invesco’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$216K Buy
+20,687
New +$153K ﹤0.01% 3568
2024
Q2 		– Sell
-8,157
Closed -$159K – 3957
2024
Q1 		$159K Buy
8,157
+6,339
+349% +$134K ﹤0.01% 3688
2023
Q4 		$37.6K Sell
1,818
-783
-30% -$23.4K ﹤0.01% 3772
2023
Q3 		$82.7K Sell
2,601
-40
-2% -$1.34K ﹤0.01% 3747
2023
Q2 		$88.7K Buy
2,641
+1,971
+294% +$70.5K ﹤0.01% 3749
2023
Q1 		$27.9K Sell
670
-23
-3% -$1.08K ﹤0.01% 3794
2022
Q4 		$23.5K Buy
+693
New +$29.5K ﹤0.01% 3964
2022
Q2 		– Sell
-999
Closed -$37K – 4126
2022
Q1 		$37K Buy
999
+59
+6% +$3.69K ﹤0.01% 3952
2021
Q4 		$92K Sell
940
-172
-15% -$18.5K ﹤0.01% 3915
2021
Q3 		$139K Buy
1,112
+141
+15% +$17K ﹤0.01% 3881
2021
Q2 		$122K Buy
971
+84
+9% +$10K ﹤0.01% 3869
2021
Q1 		$120K Buy
887
+63
+8% +$7.82K ﹤0.01% 3741
2020
Q4 		$75K Buy
+824
New +$71.5K ﹤0.01% 3687

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco's RNAC Position: Q2 2026 in Review

Invesco opened a new position in Cartesian Therapeutics (RNAC) in Q2 2026: 20,687 shares worth $216K. The stake represents ﹤0.01% of the portfolio and ranks #3568 among its holdings. This is a return to the name: Invesco previously reported a position in RNAC as recently as Q1 2024.

Invesco first reported a position in RNAC in Q4 2020 and has held it in 13 quarters since. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Invesco held 20,687 shares of Cartesian Therapeutics worth $216K as of Q2 2026.
  • Cartesian Therapeutics was a new Invesco position in Q2 2026.
  • Cartesian Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3568 holding.
  • Invesco first reported a position in Cartesian Therapeutics in Q4 2020 and has held it in 13 quarters since.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.